UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: December 22, 2017

(Date of earliest event reported)

 

LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-36562

 

46-2996673

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

281 Tresser Blvd., 9th Floor
Stamford, CT

 

06901

(Address of Principal Executive Offices)

 

(Zip Code)

 

(203) 653-3880

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 



 

Item 5.02                                            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer.

 

On December 22, 2017, David Bonita, M. D. advised the Board of Directors of Loxo Oncology, Inc. (“Loxo Oncology”) that he would resign as a Class II independent director of Loxo Oncology and as a member of the audit and compensation committees of the board of directors, effective immediately. Dr. Bonita’s resignation is not the result of any disagreement with Loxo Oncology on any matter relating to its operations, policies or practices. Following Dr. Bonita’s resignation, Steven Elms was appointed to the audit committee and Steve Harr, M.D., was appointed to the compensation committee.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Loxo Oncology, Inc.

 

 

Date: December 27, 2017

By:

/s/ Jennifer Burstein

 

Name:

Jennifer Burstein

 

Title:

Vice President of Finance and principal financial officer

 

3


LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more LOXO ONCOLOGY, INC. Charts.
LOXO ONCOLOGY, INC. (NASDAQ:LOXO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more LOXO ONCOLOGY, INC. Charts.